132 related articles for article (PubMed ID: 38663673)
1. Differential inhibition of sildenafil and macitentan on saxagliptin metabolism.
Dai GX; Tan W; Shen Y; Lin D; Xu RA; Lin Q; Wei Z
Toxicol Appl Pharmacol; 2024 May; 486():116934. PubMed ID: 38663673
[TBL] [Abstract][Full Text] [Related]
2. Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.
Boulton DW
Clin Pharmacokinet; 2017 Jan; 56(1):11-24. PubMed ID: 27282159
[TBL] [Abstract][Full Text] [Related]
3. Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.
Sidharta PN; van Giersbergen PL; Wolzt M; Dingemanse J
Br J Clin Pharmacol; 2014 Nov; 78(5):1035-42. PubMed ID: 24962473
[TBL] [Abstract][Full Text] [Related]
4. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects.
Upreti VV; Boulton DW; Li L; Ching A; Su H; Lacreta FP; Patel CG
Br J Clin Pharmacol; 2011 Jul; 72(1):92-102. PubMed ID: 21651615
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
Su H; Boulton DW; Barros A; Wang L; Cao K; Bonacorsi SJ; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2012 Jul; 40(7):1345-56. PubMed ID: 22496391
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Scheen AJ
Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
[TBL] [Abstract][Full Text] [Related]
7. Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Impact of Chronic Kidney Disease on CYP3A4-Mediated Metabolism of Saxagliptin.
Butrovich MA; Tang W; Boulton DW; Nolin TD; Sharma P
J Clin Pharmacol; 2022 Aug; 62(8):1018-1029. PubMed ID: 35247279
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections.
Fura A; Khanna A; Vyas V; Koplowitz B; Chang SY; Caporuscio C; Boulton DW; Christopher LJ; Chadwick KD; Hamann LG; Humphreys WG; Kirby M
Drug Metab Dispos; 2009 Jun; 37(6):1164-71. PubMed ID: 19251818
[TBL] [Abstract][Full Text] [Related]
9. Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions.
de Kanter R; Sidharta PN; Delahaye S; Gnerre C; Segrestaa J; Buchmann S; Kohl C; Treiber A
Clin Pharmacokinet; 2016 Mar; 55(3):369-80. PubMed ID: 26385839
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Scheen AJ
Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
[TBL] [Abstract][Full Text] [Related]
11. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
[TBL] [Abstract][Full Text] [Related]
12. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
Boulton DW; Li L; Frevert EU; Tang A; Castaneda L; Vachharajani NN; Kornhauser DM; Patel CG
Clin Pharmacokinet; 2011 Apr; 50(4):253-65. PubMed ID: 21348538
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic study of saxagliptin in healthy Chinese subjects.
Li H; Yang L; Tou CK; Patel CG; Zhao J
Clin Drug Investig; 2012 Jul; 32(7):465-73. PubMed ID: 22668067
[TBL] [Abstract][Full Text] [Related]
14. Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects.
Csonka D; Bruderer S; Schultz A; Soergel M; Stepanova R; Sabattini G; Perez-Ruixo JJ
Clin Drug Investig; 2019 Dec; 39(12):1223-1232. PubMed ID: 31552642
[TBL] [Abstract][Full Text] [Related]
15. Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.
Yang LP
Drugs; 2012 Jan; 72(2):229-48. PubMed ID: 22221000
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of drug interactions of saxagliptin with sildenafil in healthy volunteers.
Mansour RY; ElBorolossy R; Shaheen SM; Sabri NA
Eur J Clin Pharmacol; 2022 Dec; 78(12):1935-1944. PubMed ID: 36214883
[TBL] [Abstract][Full Text] [Related]
17. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
Neumiller JJ; Campbell RK
Am J Health Syst Pharm; 2010 Sep; 67(18):1515-25. PubMed ID: 20811029
[TBL] [Abstract][Full Text] [Related]
18. Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro.
Liu Q; Ou-Yang QG; Lin QM; Lu XR; Ma YQ; Li YH; Xu RA; Lin DD; Hu GX; Cai JP
Fundam Clin Pharmacol; 2022 Feb; 36(1):150-159. PubMed ID: 33961299
[TBL] [Abstract][Full Text] [Related]
19. Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen(®), a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women.
Upreti VV; Hsiang CB; Li L; Xu X; LaCreta FP; Boulton DW
Diabetes Obes Metab; 2012 Dec; 14(12):1155-7. PubMed ID: 22776778
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects.
Atsmon J; Dingemanse J; Shaikevich D; Volokhov I; Sidharta PN
Clin Pharmacokinet; 2013 Aug; 52(8):685-92. PubMed ID: 23568224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]